HepaGam B (Aptevo BioTherapeutics LLC)
Welcome to the PulseAid listing for the HepaGam B drug offered from Aptevo BioTherapeutics LLC. This Human Immunoglobulin [EPC],Passively Acquired Immunity [PE],Virus Neutralization [MoA],Virus-specific Hyperimmune Globulins [Chemical/Ingredient],Immunoglobulins [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Aptevo BioTherapeutics LLC |
| NON-PROPRIETARY NAME: | Hepatitis B Immune Globulin (Human) |
| SUBSTANCE NAME: | HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Human Immunoglobulin [EPC],Passively Acquired Immunity [PE],Virus Neutralization [MoA],Virus-specific Hyperimmune Globulins [Chemical/Ingredient],Immunoglobulins [Chemical/Ingredient] |
| ROUTE: | INTRAMUSCULAR; INTRAVENOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2016-07-01 |
| END MARKETING DATE: | 0000-00-00 |
HepaGam B HUMAN PRESCRIPTION DRUG Details:
| Item Description | HepaGam B from Aptevo BioTherapeutics LLC |
| LABELER NAME: | Aptevo BioTherapeutics LLC |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 312([iU]/mL) |
| START MARKETING DATE: | 2016-07-01 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 70504-0051_3c1dd633-2fa9-45c3-ba7a-8771d5c3b5f1 |
| PRODUCT NDC: | 70504-0051 |
| APPLICATION NUMBER: | BLA125035 |
Other HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN Pharmaceutical Manufacturers / Labelers:
